Breaking Stories

: Pfizer’s next play: A vaccine maker and pandemic ‘partner’ to governments


Pfizer Inc.’s COVID-19 vaccine is on track to generate a whopping $26 billion in sales this year, making it the drug maker’s top-selling drug and forging a new path into infectious diseases for the legacy drug maker.

Europe Markets: European stocks turn lower as focus turns to U.S. jobs report

Previous article

Need to Know: Cryptos and stocks like NIO and Tilray are crucially linked. Here’s what you need to watch, says strategist.

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *